<DOC>
	<DOCNO>NCT02546817</DOCNO>
	<brief_summary>To assess real-world safety/effectiveness Eliquis Korean venous thromboembolism ( VTE ) patient patient characteristic associate bleeding among patient take Eliquis . To identify factor might associate safety effectiveness profile Korean VTE patient .</brief_summary>
	<brief_title>Eliquis ( VTE Treatment Prevention Recurrent VTE ) rPMS</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Adult ( â‰¥19 year age ) patient initiate treatment Eliquis treatment VTE prevention recurrent VTE first time accordance Korean package insert enrol study Patients prior treatment Eliquis enrollment study Patients receive Eliquis treatment indication approve indication Korea Patients meeting follow criterion include study : ) Hypersensitivity active substance excipients ii ) Clinically significant active bleeding iii ) Hepatic disease associate coagulopathy clinically relevant bleeding risk iv ) Patients increase bleed risk due follow disease : 1 . Recent gastrointestinal ulceration history 2 . Recent intracranial intracerebral haemorrhage history 3 . Intraspinal intracerebral vascular abnormality 4 . Recent brain , spinal ophthalmic surgery history 5 . Recent brain spinal injury 6 . Known suspected oesophageal varix 7 . Arteriovenous malformation 8 . Vascular aneurysms 9 . Patients malignant neoplasms high risk bleed Concomitant treatment anticoagulant agent : ) Unfractionated heparin ( UFH ) ii ) Low molecular weight heparin ( enoxaparin , dalteparin , etc ) iii ) Heparin derivative ( fondaparinux , etc ) iv ) oral anticoagulant ( warfarin , rivaroxaban , dabigatran , etc ) except circumstance switch therapy apixaban UFH give dos necessary maintain patent central venous arterial catheter Patients rare hereditary problem galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Treatment</keyword>
	<keyword>Tx</keyword>
	<keyword>Prevent</keyword>
</DOC>